Last Updated: Thursday, September 12, 2024
The Site of Care Drug Management Program designed to improve the experience for members using certain medically billed infusion drugs that are considered safe and effective for administration outside of a hospital setting. The program helps decrease the cost of care for these therapies by ensuring appropriate utilization of the drugs through medical policy and a prior authorization requirement.
With the implementation of this program, the medical policies for these drugs were revised to incorporate a medical necessity review for the requested site of care in addition to the already existing review that takes place for clinical appropriateness of the drug therapy.
Approved sites of care include the following:
*FOR NEW YORK ONLY: All in-network hospital-based facilities will be considered approved sites of care during the authorization review process for members to receive their infusion medication for at least 2022, until further notice. All out-of-network and out-of-area hospital facilities will still be considered non-approved sites and subject to the terms of the Site of Care Policy I-151.
The list of Site of Care drugs can be found:
Effective July 1, 2024, West Virginia Law (Senate Bill 267) mandates the electronic submission of prior authorization requests. For this reason, Highmark removed West Virginia prior authorization forms from the Provider Resource Center (PRC). All prior authorization requests must now be submitted to Highmark via our provider portal (Availity).
Related Links
Additional information on Prescription Drug Programs can be found in the Highmark Provider Manual.